|Back to main|
Positive Data on BSTC's Xiaflex - Analyst Blog
4/1/2013 7:05:00 PM
) recently announced positive top line data from a phase IIa
study on Xiaflex for the potential treatment of frozen shoulder
syndrome (FSS) in adults. BioSpecifics has a strategic
Auxilium Pharmaceuticals, Inc.
) for Xiaflex.
The study involved 50 adults, equally divided into 5 groups.
Four such cohorts received up to three injections of Xiaflex
(doses ranging from 0.29 mg to 0.58mg in three different volumes:
0.5, 1.0, or 2.0 mL) in addition to home shoulder exercises. The
fifth cohort only performed home shoulder exercises.
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
BIOSPECIFICS TE (BSTC): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
WUXI PHARMATECH (WX): Free Stock Analysis Report
To read this article on Zacks.com click here.